|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suh DH, Kim JW, Kim K, Kim HJ and Lee KH:
Major clinical research advances in gynecologic cancer in 2012. J
Gynecol Oncol. 24:66–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maldonado L and Hoque MO: Epigenomics and
ovarian carcinoma. Biomark Med. 4:543–570. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei
Y, Li Y, Yang Q, Liu J, Wei JJ, et al: miR-145 inhibits tumor
growth and metastasis by targeting metadherin in high-grade serous
ovarian carcinoma. Oncotarget. 5:10816–10829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yiwei T, Hua H, Hui G, Mao M and Xiang L:
HOTAIR Interacting with MAPK1 regulates ovarian cancer skov3 cell
proliferation, migration, and invasion. Med Sci Monit.
21:1856–1863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dwivedi SK, Mustafi SB, Mangala LS, Jiang
D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P,
Calin GA, et al: Therapeutic evaluation of microRNA-15a and
microRNA-16 in ovarian cancer. Oncotarget. 7:15093–15104. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen X, Dong C, Law PT, Chan MT, Su Z,
Wang S, Wu WK and Xu H: MicroRNA-145 targets TRIM2 and exerts
tumor-suppressing functions in epithelial ovarian cancer. Gynecol
Oncol. 139:513–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo J, Zhou J, Cheng Q, Zhou C and Ding Z:
Role of microRNA-133a in epithelial ovarian cancer pathogenesis and
progression. Oncol Lett. 7:1043–1048. 2014.PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmiedel JM, Klemm SL, Zheng Y, Sahay A,
Bluthgen N, Marks DS and van Oudenaarden A: Gene expression.
MicroRNA control of protein expression noise. Science. 348:128–132.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasaki H, Yoshiike M, Nozawa S, Usuba W,
Katsuoka Y, Aida K, Kitajima K, Kudo H, Hoshikawa M, Yoshioka Y, et
al: Expression level of urinary microRNA-146a-5p is increased in
patients with bladder cancer and decreased in those after
transurethral resection. Clin Genitourin Cancer. 14:e493–e499.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Jin L, Chen D, Liu J, Su Z, Yang S,
Gui Y, Mao X, Nie G and Lai Y: Tumor suppressive miR-196a is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Mol Med Rep. 14:560–566. 2016.PubMed/NCBI
|
|
17
|
Chen Z, Liu H, Jin W, Ding Z, Zheng S and
Yu Y: Tissue microRNA-21 expression predicted recurrence and poor
survival in patients with colorectal cancer-a meta-analysis. Onco
Targets Ther. 9:2615–2624. 2016.PubMed/NCBI
|
|
18
|
Tao S, Liu YB, Zhou ZW, Lian B, Li H, Li
JP and Zhou SF: miR-3646 promotes cell proliferation, migration,
and invasion via regulating G2/M transition in human breast cancer
cells. Am J Transl Res. 8:1659–1677. 2016.PubMed/NCBI
|
|
19
|
Wang N, Wang Q, Shen D, Sun X, Cao X and
Wu D: Downregulation of microRNA-122 promotes proliferation,
migration, and invasion of human hepatocellular carcinoma cells by
activating epithelial-mesenchymal transition. Onco Targets Ther.
9:2035–2047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen H, Zhang L, Zhang L, Du J, Wang H and
Wang B: MicroRNA-183 correlates cancer prognosis, regulates cancer
proliferation and bufalin sensitivity in epithelial ovarian caner.
Am J Transl Res. 8:1748–1755. 2016.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Duan B, Dong Y, He C, Zhou H, Sheng
H, Gao H and Zhang X: MicroRNA-139-3p indicates a poor prognosis of
colon cancer. Int J Clin Exp Pathol. 7:8046–8052. 2014.PubMed/NCBI
|
|
24
|
Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu
Y, Yin L and Kim SJ: Tumor-suppressive function of miR-139-5p in
esophageal squamous cell carcinoma. PLoS One. 8:e770682013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo J, Miao Y, Xiao B, Huan R, Jiang Z,
Meng D and Wang Y: Differential expression of microRNA species in
human gastric cancer versus non-tumorous tissues. J Gastroenterol
Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corbetta S, Vaira V, Guarnieri V,
Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini
I, Bisceglia M, Beck-Peccoz P, et al: Differential expression of
microRNAs in human parathyroid carcinomas compared with normal
parathyroid tissue. Endocr Relat Cancer. 17:135–146. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gu W, Li X and Wang J: miR-139 regulates
the proliferation and invasion of hepatocellular carcinoma through
the WNT/TCF-4 pathway. Oncol Rep. 31:397–404. 2014.PubMed/NCBI
|
|
29
|
Wang H, Yan X, Ji LY, Ji XT, Wang P, Guo
SW and Li SZ: miR-139 functions as an antioncomir to repress glioma
progression through targeting IGF-1 R, AMY-1, and PGC-1β. Technol
Cancer Res Treat. Feb 10–2016.(Epub ahead of print).
|
|
30
|
Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun
H, Jiang Y, Zhang W, Liang A, Guo Y, et al: miR-139-5p suppresses
cancer cell migration and invasion through targeting ZEB1 and ZEB2
in GBM. Tumour Biol. 36:6741–6749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y,
Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al: MiR-139 inhibits Mcl-1
expression and potentiates TMZ-induced apoptosis in glioma. CNS
Neurosci Ther. 19:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren Y, Zhu H, Chi C, Yang F and Xu X:
MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt
signaling pathway. Int J Clin Exp Pathol. 8:4588–4594.
2015.PubMed/NCBI
|
|
33
|
Zhang HD, Sun DW, Mao L, Zhang J, Jiang
LH, Li J, Wu Y, Ji H, Chen W, Wang J, et al: MiR-139-5p inhibits
the biological function of breast cancer cells by targeting Notch1
and mediates chemosensitivity to docetaxel. Biochem Biophys Res
Commun. 465:702–713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bao C, Wang J, Ma W, Wang X and Cheng Y:
HDGF: A novel jack-of-all-trades in cancer. Future Oncol.
10:2675–2685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang JS, Chao CC, Su TL, Yeh SH, Chen DS,
Chen CT, Chen PJ and Jou YS: Diverse cellular transformation
capability of overexpressed genes in human hepatocellular
carcinoma. Biochem Biophys Res Commun. 315:950–958. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu XJ, Liu WL, Yang FM, Yang XQ and Lu
XF: Hepatoma-derived growth factor predicts unfavorable prognosis
of epithelial ovarian cancer. Onco Targets Ther. 8:2101–2109.
2015.PubMed/NCBI
|
|
37
|
Sun B, Gu X, Chen Z and Xiang J: MiR-610
inhibits cell proliferation and invasion in colorectal cancer by
repressing hepatoma-derived growth factor. Am J Cancer Res.
5:3635–3644. 2015.PubMed/NCBI
|
|
38
|
Wu D, Niu X, Pan H, Zhang Z, Zhou Y, Qu P
and Zhou J: MicroRNA-497 targets hepatoma-derived growth factor and
suppresses human prostate cancer cell motility. Mol Med Rep.
13:2287–2292. 2016.PubMed/NCBI
|
|
39
|
Guo H, Li W, Zheng T and Liu Z: MiR-195
targets HDGF to inhibit proliferation and invasion of NSCLC cells.
Tumour Biol. 35:8861–8866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen B, Huang T, Jiang J, Lv L, Li H and
Xia S: miR-141 suppresses proliferation and motility of gastric
cancer cells by targeting HDGF. Mol Cell Biochem. 388:211–218.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC,
Huang CH, Lee YS, Yen TC and Hsieh SY: MicroRNA-214 downregulation
contributes to tumor angiogenesis by inducing secretion of the
hepatoma-derived growth factor in human hepatoma. J Hepatol.
57:584–591. 2012. View Article : Google Scholar : PubMed/NCBI
|
